课题基金 / 基金详情

NOVEL SEROTONIN UPTAKE INHIBITOR LIGANDS

NOVEL SEROTONIN UPTAKE INHIBITOR LIGANDS
新型血清素摄取抑制剂配体
批准号:
2039118
负责人:
JOHN M GERDES
金额:
$9.72万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-05-15 至 2000-04-30

项目摘要

项目成果

JOHN M GERDES的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The serotonin (5-HT) transporter complex is a protein located on the pre-synaptic side of serotonergic neurons in the central nervous system and is involved in regulating concentrations of 5-HT (uptake) in the synaptic cleft. This protein contains a binding site for serotonin and is thought to play a critical role in a variety of mental health disorders. The 5-HT binding site can be blocked. This site has been-shown to be the target of many of the commercial, highly selective antidepressants and also of drugs of abuse, including cocaine. Our long-term objective is to further elucidate the structure of the 5-HT uptake inhibitor binding site. The study will develop new chemical probes and perform computational modeling studies in order to refine a prelminary three-dimensional model of the inhibitorypharmacophore and employ computer-aided three- dimensional quantitative structure-affinity relationship (3D-QSAR) comparative molecular field analyses to map the 5-HT uptake binding site. To accomplish these goals, our specific aims encompass I)the syntheses and in vitro binding evaluations of semi-rigid and flexible quinolyl- and indolylphenylalkylamine molecules; 2) the syntheses and assessments of in vitro binding at the 5-HT uptake receptor of phenylazepinoindole ligands and also dinor-12- hydyroxyibogaine; and 3) computer-aided modeling employing an active analog approach effected by template forcing, conformational analyses for construction and refinement of the ligand based pharmacophore 5-HT uptake model followed by the utilization of a refined pharmacophore model for the application of a 3D-QSAR comparative molecular field analysis. The resultant binding site map may prove to be potentially useful for its binding affinity prediction value which will be used for the design of other structurally novel drugs with enhanced biochemical properties and high binding affinities for the serotonin uptake site. New drugs afforded from this design paradigm may find application as new therapies or as diagnostic tools in serotonin related mental health disorders.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
First-in-Human evaluation of an astrocytic glutamate transporter (EAAT2) PET tracer in healthy and Alzheimer's diseased brain
First-in-Human evaluation of an astrocytic glutamate transporter (EAAT2) PET tracer in healthy and Alzheimer's diseased brain
Nonhuman Primate CNS Assessments of 18F-Insulin After IntranasalAdministration
  • 批准号:
    9762775
  • 项目类别:
  • 资助金额:
    $12.58万
  • 财政年份:
    2017
  • 负责人:
    JOHN M GERDES
  • 依托单位:
Nonhuman Primate CNS Assessments of 18F-Insulin After Intranasal Administration
海外基金